Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant’s wide-ranging portfolio was crucial to that haul but the company’s next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb’s competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.
Looking for leads, investment insights, or competitive intelligence?
News about Merck
Must-read business news, delivered every morning.
A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half.
The new cure could be a boon to poorer nations.
Alzheimer's drug development has been a tale of heartbreaks and setbacks.